Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If the Sec was investigating OW they would have put an end on trading here. Period ! Jeff new what he did and it’s his responsibility of his own actions, once the dust settles from all this he may end up having to pay OW back for legal damages for selling long term held shares.
Everyone get your Tin Foil Hats On..lol
I come to found out you only know Pump and more Pump oh and scam to..lol..Pump up the volume !!
You got that right !!
I think you might be dilutional..
DD Please...Dont make speculations !
This is far Off from any DD you have done...
I call BS and more BS !
You should really do your DD...There is more to the story then meets the eye.
OW is far ahead on the research end. This company is just starting out.
Blah blah blah...Show us the insider proof ?
Yup just Block the NEG BS !! :)
Show us that insiders are doing wash Trades ?? BS !
OW wants him out I dont think he has a choice in the matter, but in a orchestrated way, Once he is out we should be in a better position for movement.
This is the calm before the storm..The Data will be out and your tune will change , Mark this Post !
This is just the beginning..
Just like when you took a trip to Isreal to visit the company..lol
Show me where its approved ? Its not approved the FDA is still looking for more patient DATA.
I think we are all waiting for the pics and updates you had. Which were all BS !
This won't be held down to much longer..
GWPH still has work to do...
Its an oldie but a goodie..I have a feeling we will be re-visiting this..
https://insiderfinancial.com/owc-pharmaceutical-research-corp-otcmktsowcp-could-be-the-next-gw-pharmaceuticals-plc-adr-nasdaqgwph
And they are still not approved here in the states, The FDA here needs more Patient Data. I dont think you understand, I know how clinical trials work. Do some DD.
Cannabis-based Sublingual Tablet to Enter Trials in Israel as Possible Spasticity Treatment, OWCP Says
DECEMBER 20, 2018 Alice MelãoBY ALICE MELÃO IN NEWS.
Cannabis-based Sublingual Tablet to Enter Trials in Israel as Possible Spasticity Treatment, OWCP Says
OWC Pharmaceutical Research is planning new clinical studies to evaluate the activity and safety of its cannabinoid-enriched sublingual soluble tablet. The company announced that an Institutional Review Board (IRB) in Israel approved its request to conduct a safety and tolerability trial there.
The company also is asking to amend the study design, allowing the trial to compare its tablet formulation with the known cannabis-based therapy Sativex (nabiximols, by GW Pharmaceuticals), a nasal spray that is approved in Europe and elsewhere to treat spasticity in patients with multiple sclerosis (MS). Sativex is not approved by the U.S. Food and Drug Administration (FDA) for use in that country.
The Israel Medical Cannabis Agency (IMCA) also gave OWCP permission to conduct a study looking at the efficacy of the cannabinoid-enriched sublingual disintegrating tablet in treating chronic pain syndrome.
.
These studies are planned to take place at the Sourasky Academic Medical Center in Tel Aviv, and are expected to start in early 2019.
“OWCP’s sublingual disintegrating tablet will offer an alternative to smoking and inhalation, allowing for controlled, consistent dosing and diligent compliance to medical regimens and offer quick pain and other symptoms relief as sublingual absorption provides a direct route for cannabis to enter much quicker to the blood system,” Mordechai Bignitz, the company’s CEO, said in a press release.
Increasing evidence suggests that cannabis and cannabinoid-based products can help patients manage the symptoms of various diseases, including MS. Studies have demonstrated that such medicines can reduce pain, uncontrolled contraction of muscles, and muscle stiffness (spasticity).
As a result of its therapeutic benefits, cannabinoid-based products are increasingly available and requested by patients. It is estimated that about 16 percent of MS patients use cannabis for medicinal purposes.
Medical cannabis is most commonly administered are through smoking and inhalation. But OWCP in its release and other researchers note that these methods can lack precision in terms of the amount or concentration of active cannabinoids in the therapy. Smoking is also linked to potentially damaging side effects, and is increasingly viewed negatively in social situations.
OWCP said it developed the cannabinoid-enriched sublingual soluble tablets to provide an effective alternative to smoking.
Why any one would sell now is beyond me, We are on the cusp of some great news in the foreable future.
Tides will turn soon. Mark This Post !
OWC Pharmaceutical Research Corp. Reports the Successful Production of Its Cannabinoid-Enriched Sublingual Disintegrating Tablet
PR Newswire PR Newswire•December 18, 2018
RAMAT GAN, Israel, Dec. 18, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, reports the successful production of its cannabinoid-enriched sublingual disintegrating tablet, specifically developed as smoking substitute.
OWC Logo (PRNewsfoto/OWC Pharmaceutical Research Cor)
OWC Logo (PRNewsfoto/OWC Pharmaceutical Research Cor)
More
Smoking and inhalation are currently the most common using methods of administering medical cannabis. However, the precise concentration of active cannabinoids in inflorescences is inconsistent and difficult to determine. In addition, smoking may have deleterious side effects and social acceptance issues, which may reduce compliance of drug administration. "OWCP's sublingual disintegrating tablet will offer an alternative to smoking and inhalation, allowing for controlled, consistent dosing and diligent compliance to medical regimens and offer quick pain and other symptoms relief as Sublingual absorption provides a direct route for cannabis to enter much quicker to the blood system," said Mordechai Bignitz, CEO at OWC Pharmaceutical Research Corp.
OWCP now reports that it has completed the successful production of its sublingual tablet, which will allow the company to begin its clinical testing program for this dosing form. OWCP has received an IRB approval to conduct a pharmaco-kinetic (PK) safety study of its sublingual tablet. In addition, OWCP has applied for an amendment to its study protocols to enable the comparison of its tablet with a known cannabis-based pharmaceutical, which is registered for treatment of spasticity in Multiple Sclerosis patients. The company has also received a permit from the IMCA (Israel Medical Cannabis Agency) to conduct an efficacy study of the tablet on chronic pain syndrome.
The studies will be conducted at the Sourasky Academic Medical Center in Tel Aviv and are expected to start in the first quarter of 2019. Tel Aviv Sourasky Medical Center is the largest acute care facility in Israel, treating about 400,000 patients and hosting 1.8 million patient visits per year. A 1500-bed world-class governmental academic medical center, Tel Aviv Sourasky Medical Center serves a population of one million people, including residents from the greater Tel Aviv area and visitors to the metropolis.
About OWC Pharmaceutical Research Corp
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively 'OWC' or the 'Company') conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
OWCP is also developing unique and effective delivery systems and dosage forms of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators.
Contact:
Mordechai Bignitz
Chief Executive Officer
OWC Pharmaceutical Research Corp.
info@owcpharma.com
Tel: +972-(72)-260-8004
I have a feeling she was ok with it from the very beginning by the timeline of there relationship and she over re-acted in someway to hurt his reputation.
"Baruch said in response: “Since I wanted to sever the romantic relationship between myself and Ms. Berger — a consensual relationship between two adults that was conducted with the knowledge and approval of Ms. Berger’s parents — Ms. Berger made it her goal to harm me in every possible way. She did this by spreading lies, false complaints to the Israel Police, a false complaint to the Health Ministry and by means of appeals to journalists in various media outlets, exactly as she had threatened to do on the eve of the severing of our relationship.
Friedland should have known better for what he did, that’s his problem, He may very well have some legal issues for what he did with OWCP and have to re-pay $$ toward the company for his wrong doings, OW’s management was unaware of his actions when he
Sold shares.
Quite True ! Its coming
OWC Pharmaceutical Research Corp. to Report Progress in Clinical Trials for Ointment Care for Skin Diseases
PR Newswire
RAMAT GAN, Israel, Nov. 29, 2018
RAMAT GAN, Israel, Nov. 29, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, reported today that the safety study of cannabis-based topical ointment, conducted at Shiba Shiba Academic Medical Center, is close to completion as the last healthy volunteer started the treatment three weeks ago. The subject of study is expected to be treated with the ointment during six weeks.
OWC Logo (PRNewsfoto/OWC Pharmaceutical Research Cor)
Also, earlier this month OWC Pharmaceutical aroused high level of interest and caught the attention of the industry at MJBizCon. Mr. Mordechai Bignitz, OWC Pharmaceutical CEO said: "MJBizCon was an excellent opportunity for OWC Pharmaceutical to reveal its innovative research and to present the progress and pipeline to investors and potential partners. We look forward to accelerate new opportunities as we strongly believe that our innovative clinical research can unlock the potential of cannabis-based treatment and improve patients' quality of life."
About OWC Pharmaceutical Research Corp
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively 'OWC' or the 'Company') conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
OWCP is also developing unique and effective delivery systems and dosage forms of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators.
Contact: Mordechai Bignitz , Chief Executive Officer - OWC Pharmaceutical research crop,
info@owcpharma.com, Tel: +972-(72)-260-8004
Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/owc-pharmaceutical-research-corp-to-report-progress-in-clinical-trials-for-ointment-care-for-skin-diseases-300757541.html
SOURCE OWC Pharmaceutical Research Corp.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
OTCQB Member Since 03/2015
OTCQB
OTCQB Venture
Verified Profile 10/2018
Transfer Agent Verified
Think he is hiding out today..lol
Has nothing to do with this OWCP. Owcp has Patents listed, this company was a total shell.
There is no Investigation ! Period !
Ahhh don't be so empty hearted..
Yea send us Pics..lol and more BS !